Hutchmed (china) vs Tarsus Pharmaceuticals
Hutchmed (china) is the larger business, with $549m of revenue in fiscal 2025 against $451m for Tarsus Pharmaceuticals (1.2 times as much). Tarsus Pharmaceuticals grew faster (146.7% against -13.0%). Hutchmed (china) kept more of each dollar of sales as profit: a net margin of 83.3% against -14.7%. Hutchmed (china) carries less debt relative to equity (9.5% against 21.8%).
| Latest fiscal year | Hutchmed (china)HCM, 2025 | Tarsus PharmaceuticalsTARS, 2025 |
|---|---|---|
| Revenue | $549m | $451m |
| Revenue growth | -13.0% | 146.7% |
| Net income | $457m | −$66.4m |
| Operating margin | -7.1% | -15.7% |
| Net margin | 83.3% | -14.7% |
| Return on equity | 45.7% | -23.4% |
| Free cash flow | −$78.8m | −$22.3m |
| Cash | $71.3m | $184m |
| Total debt | $118m | $75.0m |
| Debt to equity | 9.5% | 21.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 370 |
| Market value | $2.29bn | $3.09bn |
| Price vs our value range | Above our value range | — |
| Moat score | — | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 59 sales |